This webinar will provide the participant with a review of the latest pharmacologic treatment guidelines for adults with Type 2 Diabetes Mellitus (T2DM). Type 2 Diabetes Mellitus affects an estimated 9.4 percent of the population, or 30.2 million adults over the age of 18, increasing with age. Diabetes is a leading risk factor for heart disease, stroke, and kidney disease. When patients are treated to recommended glucose targets, these risk factors significantly decrease. The recommended pharmacotherapy drug classes will be explored, with a stepped approach to prescribing these medications utilizing case-based discussions.